NCT03328078 · Interventional trial
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Overall registry status Recruiting
Phase 1 · Phase 2
Conditions Refractory Hematologic Malignancy, Refractory Primary Central Nervous System Lymphoma, Relapsed Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma
Delaware Valley sites
- Hospital of the University of Pennsylvania · Philadelphia, PA · Philadelphia County · Completed
First posted
Registry updated
Added to the directory